SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is becoming the main subtype of heart failure, but lacks proven effective therapies. Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, a new kind of oral glucose-lowering agent, shows a great effect on improving cardiovascular outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Danning, Zhang, Yu, Yan, Jie, Liu, Ming, An, Fengshuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492916/
https://www.ncbi.nlm.nih.gov/pubmed/36158789
http://dx.doi.org/10.3389/fcvm.2022.942125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492916/
https://www.ncbi.nlm.nih.gov/pubmed/36158789
http://dx.doi.org/10.3389/fcvm.2022.942125

Ejemplares similares